HOME >> BIOLOGY >> NEWS
New findings point to new target to block angiogenesis

NASHVILLE, Tenn. - Cutting off supply lines is a sure way to strangle and defeat an enemy army. The strategy is being applied to the war against tumors, which require supply lines-new blood vessels-to support their growth and metastasis. Scientists at the Vanderbilt-Ingram Cancer Center have identified an unexpected participant in the process of blood vessel development. Reported in the Sept. 15 issue of the journal Cancer Research, their findings point to a new target for drugs that inhibit this process, angiogenesis.

Previous work from multiple laboratories had suggested that the enzyme cyclooxygenase-2 (COX-2) contributes to the blood vessel development associated with tumors. To determine which of many COX-2 products participate in angiogenesis, Dr. Thomas Daniel, director of Vanderbilt's Vascular Biology Center, took advantage of a cultured endothelial cell system developed in his laboratory. The cultured cells migrate in response to angiogenic signals, just as they would in order to form new blood vessels in vivo.

Collaborator Dr. Jason D. Morrow, a professor of Medicine and Pharmacology, used a technique called mass spectrometry to establish that the activated endothelial cells generate the COX-2 products PGE2, thromboxane A2, and PGF2alpha. COX-2 inhibitors developed by biochemist Lawrence J. Marnett, Ph.D., associate director of research programs at the Vanderbilt-Ingram Cancer Center, prevented the formation of all of these products and blocked the cell migration response. Of the three products, only thromboxane A2 turned out to have a functional role in endothelial cell migration.

"Adding back thromboxane A2 under COX-2-inhibited conditions reconstituted cell migration," Daniel said.

Drugs that block the thromboxane A2 receptor also halted endothelial cell migration.

Using a model of angiogenesis in the mouse cornea, Daniel showed that the findings were not limited to cultured cells. "All of our in vitro observations implicating throm
'"/>

Contact: Cynthia Manley
cynthia.manley@mcmail.vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
15-Sep-1999


Page: 1 2

Related biology news :

1. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
2. Virginia Tech researchers to release findings on Smith River Project
3. New HIV findings
4. Stanford researchers findings may shed light on common, deadly birth defect
5. Briggs takes to the molecular level Darwins findings on plants sensing the direction of light
6. Latest findings on PCBs to be subject of June workshop at Illinois
7. Chlamydia in men now also linked to infertility new findings
8. New MS research shows remarkable findings
9. Scientists findings may lead to better understanding of how that sleep develops, matures
10. New findings are a window into the late stages of Lou Gehrigs disease
11. New findings bring mixed blessings to those looking to combat jet lag

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/30/2017)... June 30, 2017 Today, American Trucking ... supplier of face and eye tracking software, became ... provider program. "Artificial intelligence and ... to monitor a driver,s attentiveness levels while on ... able to detect fatigue and prevent potential accidents, ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
Cached News: